1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Exocrine Pancreatic Insufficiency (EPI) -Market Insights, Epidemiology and Market Forecast– 2030

Exocrine Pancreatic Insufficiency (EPI) -Market Insights, Epidemiology and Market Forecast– 2030

  • April 2021
  • 180 pages
  • ID: 5879449
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Exocrine Pancreatic Insufficiency (EPI) -Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Exocrine Pancreatic Insufficiency (EPI), historical and forecasted epidemiology as well as the Exocrine Pancreatic Insufficiency (EPI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Exocrine Pancreatic Insufficiency (EPI) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Exocrine Pancreatic Insufficiency (EPI) market size from 2017 to 2030. The report also covers current Exocrine Pancreatic Insufficiency (EPI) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030

Exocrine Pancreatic Insufficiency (EPI) Disease Understanding and Treatment Algorithm

Exocrine Pancreatic Insufficiency (EPI) Overview
Exocrine pancreatic insufficiency (EPI) refers to the presence of maldigestion and malabsorption of such nutrients. It is a consequence of the primary loss of functional parenchyma and/or secondarily impaired exocrine pancreatic function and insufficient pancreatic enzyme activity. EPI is sometimes defined simply as an enzyme output less than 10% of that necessary to sustain normal digestion; however, there is no consensus in the literature on the definition of EPI. Furthermore, the clinical presentation of EPI can vary widely depending on the underlying cause, as well as disease stage, diet, and other factors. EPI is most commonly caused by diseases that destroy the pancreatic parenchyma, such as chronic pancreatitis and cystic fibrosis, as well as pancreatic resection. The incidence of EPI in chronic pancreatitis ranges from 30% of patients with mild disease to 85% with severe disease. Approximately 85% of infants with cystic fibrosis have EPI at birth.
There are several causes of Exocrine Pancreatic Insufficiency (EPI) which include Diabetes, Pancreatic cancer, Celiac disease, HIV/AIDS, Chronic Pancreatitis, Cystic Fibrosis Ulcerative Colitis, Schwachman–Diamond Syndrome, and others.
Exocrine Pancreatic Insufficiency (EPI) Diagnosis
The diagnostic approach to EPI can be addressed to evaluate the maldigestion of nutrients or to quantify the exocrine pancreatic secretion specifically. Two categories of tests can be distinguished: direct and indirect. Indirect tests assess the consequence of exocrine insufficiency, evaluating quantitative changes of pancreatic secretion. Direct tests evaluate the secretive production directly, and, despite their good sensitivity, are invasive, time-consuming, expensive, and not useful in monitoring the response to pancreatic enzyme replacement therapy (PERT). Moreover, they are not standardized because of lack of consensus about protocol, and present extensive variation in results, and are not widely available. The indirect tests includes Stool tests Coefficient of fat absorption, Fecal elastase-1 (FE-1), Stool chymotrypsin, Blood test Serum immunoreactive trypsinogen (IRT), and others whereas the direct tests for EPI includes Endoscopic secretin or CCK based pancreatic stimulation test, and Secretin-enhanced magnetic resonance cholangiopancreatography (s-MRCP).

Exocrine Pancreatic Insufficiency (EPI) Treatment
Patients with EPI may be treated with Pancreatic enzyme replacement therapy (PERT) to aid in the digestion and absorption of fats; PERT is recommended for patients with EPI to address weight loss, malnutrition, and steatorrhea. Briefly, treatment is primarily based on oral PERT regimens to correct malnutrition and improve symptoms. The current drugs that fall under PERT includes Creon, Zenpep, Pancreaze, Viokase, and Pertzye respectively, Underlying diseases leading to EPI should be treated, and lifestyle modifications should also be undertaken, including alcohol abstinence (to reduce pain and increase gastric lipase secretion) and supplementation of fat-soluble vitamins as needed. Dietary fat restriction is not necessary, especially for patients on enzyme supplementation. Frequent, low-volume meals are recommended, and difficult-to-digest foods such as legumes should be avoided.
It covers the details of conventional and current medical therapies available in the Exocrine Pancreatic Insufficiency (EPI) market for the treatment of the various types of Exocrine Pancreatic Insufficiency (EPI). It also provides the treatment guidelines and algorithms of the United States and Europe. The’s Exocrine Pancreatic Insufficiency (EPI) market report gives a thorough understanding of Exocrine Pancreatic Insufficiency (EPI) by including details such as disease definition, causes, risk factors, pathogenesis, and diagnosis.

Exocrine Pancreatic Insufficiency (EPI) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalence of Causative Indications of EPI and Prevalence of Exocrine Pancreatic Insufficiency scenario of Exocrine Pancreatic Insufficiency (EPI) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Key Findings
This section provides glimpse of the Exocrine Pancreatic Insufficiency (EPI) epidemiology in the 7MM.
• In the 7MM, the highest prevalence of Causative Indications of EPI was observed in Type 2 Diabetes Mellitus which was estimated to be 67,892,836 cases in 2017 during the forecast period (2020–2030).
• As per the estimates in Japan, 61,961, 66,261, 11,721, 25,319 patients were affected by Acute Pancreatitis, Chronic Pancreatitis, Cystic Fibrosis and Unresectable Pancreatic Cancer in 2017, respectively, which are anticipated to increase in the forecast period.
• Acute Pancreatitis, Chronic Pancreatitis, Cystic Fibrosis and Unresectable Pancreatic Cancer are assumed to play the foremost role in the development of EPI.

Country Wise- Exocrine Pancreatic Insufficiency (EPI) Epidemiology
The epidemiology segment also provides the Exocrine Pancreatic Insufficiency (EPI) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Exocrine Pancreatic Insufficiency (EPI) Drug Chapters
The drug chapter segment of the Exocrine Pancreatic Insufficiency (EPI) report encloses the detailed analysis of Exocrine Pancreatic Insufficiency (EPI) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Exocrine Pancreatic Insufficiency (EPI) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
Exocrine Pancreatic Insufficiency (EPI) Marketed Drugs
Pertzye (pancrelipase): Digestive Care
Pertzye (pancrelipase)—a combination of porcine-derived lipases, proteases, and amylases—developed by Digestive Care is an orally administered drug in patients with exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. The pancreatic enzymes in Pertzye catalyze the hydrolysis of fats to monoglyceride, glycerol, and free fatty acids; proteins into peptides and amino acids; and starches into dextrins and short-chain sugars—maltose and maltotriose—in the duodenum and proximal small intestine, thereby, acting like digestive enzymes secreted by the pancreas physiologically. Digestive Care and its marketing partner Chiesi, in July 2017, announced FDA approval of a 24,000 USP lipase units capsule of Pertzye (pancrelipase) delayed-release capsules to treat exocrine pancreatic insufficiency (EPI). The newly available dosing strength caters specifically to children over 12 months and adults, which may allow for consumption of fewer capsules to reach the needed weight-based dose when compared to the other Pertzye capsule sizes.
Products detail in the report…
Creon (pancrelipase)/Lipacreon: AbbVie
Creon capsule, initially developed by Solvay Pharmaceuticals, is a pancrelipase—a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of EPI due to cystic fibrosis or other conditions. In June 2011, Abbott announced that the FDA had approved an infant-specific dose of Creon (pancrelipase) delayed-release capsules to treat EPI due to cystic fibrosis (CF). In April 2011, Abbott and Eisai received approval to market the pancreatic enzyme replacement drug Lipacreon (pancrelipase) in Japan as a pancreatic digestive enzyme replacement in patients with pancreatic exocrine insufficiency.
Products detail in the report…
Zenpep (pancrelipase): Nestle
In August 2009, Eurand announced the commercial availability of Zenpep (pancrelipase) delayed-release capsules, a pancreatic enzyme product (PEP) indicated for the treatment of exocrine pancreatic EPI due to cystic fibrosis (CF) or other conditions. In January 2007, Zenpep received a fast track designation from the US FDA. In January 2020, Nestle announced that it has entered into an asset purchase agreement with Allergan to acquire Zenpep. This move aims to expand the company’s medical nutrition business and complement its portfolio of therapeutic products.
Products detail in the report…

Exocrine Pancreatic Insufficiency (EPI) Emerging Drugs
MS1819-SD: AzurRx BioPharma
AzurRx BioPharma specializes in the development of non-systemic, recombinant therapies for gastrointestinal diseases. The company is developing MS1819-SD, a yeast-derived recombinant lipase—an enzyme that breaks up fat molecules—for EPI associated with chronic pancreatitis (CP) and cystic fibrosis (CF). Also, MS1819-SD is considered recombinant because it was created from new combinations of genetic material in yeast called yarrowia lipolytica. The drug id currently in phase II clinical developmental trial in patients with EPI. The study enrolled 24 participants, and it is estimated to be complete by December 2020.
Products detail in the report…

Exocrine Pancreatic Insufficiency (EPI) Market Outlook
The treatment landscape of EPI majorly includes pancreatic enzyme replacement therapy (PERT), lifestyle modifications (e.g., avoidance of fatty foods, limitation of alcohol intake, cessation of smoking, and consumption of a well-balanced diet) and vitamin supplementation (primarily the fat-soluble vitamins A, D, E, and K). Pancreatic enzyme replacement therapy (PERT) is the first line therapeutic mainstay that is prescribed in patients. The pancreatic enzyme products (PEPs) used for PERT are extracts of porcine pancreas that contain all three pancreatic enzymes (i.e., amylase, protease, and lipase) in varying proportions. However, it is lipase that plays the paramount role in therapy. Pharmacological therapies are the mainstay treatment option followed by the patients with EPI. The market of EPI includes use of the drugs either as monotherapy and are not interchangeable. There are several approved drugs in the market of different classes.
The Exocrine Pancreatic Insufficiency (EPI) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Exocrine Pancreatic Insufficiency (EPI) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of Exocrine Pancreatic Insufficiency (EPI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the analyst, Exocrine Pancreatic Insufficiency (EPI) 7MM market is expected to change in the study period 2017–2030.

Key Findings
This section includes a glimpse of the Exocrine Pancreatic Insufficiency (EPI) 7MM market.
• The United States accounts for the largest market size of Exocrine Pancreatic Insufficiency (EPI), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
• The market size of Exocrine Pancreatic Insufficiency (EPI) in the seven major markets is USD 1,695.26 Million in 2017 for the study period (2017–2030).

The United States Market Outlook
This section provides the total Exocrine Pancreatic Insufficiency (EPI) market size and market size by therapies in the United States.

EU-5 Market Outlook
The total aspregillosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook
The total Exocrine Pancreatic Insufficiency (EPI) market size and market size by therapies in Japan are provided.

Exocrine Pancreatic Insufficiency (EPI) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Exocrine Pancreatic Insufficiency (EPI) market or expected to get launched in the market during the study period 2017–2030. The analysis covers Exocrine Pancreatic Insufficiency (EPI) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Exocrine Pancreatic Insufficiency (EPI) Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Exocrine Pancreatic Insufficiency (EPI) emerging therapies.

Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Exocrine Pancreatic Insufficiency (EPI) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
• The report covers the descriptive overview of Exocrine Pancreatic Insufficiency (EPI), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
• Comprehensive insight has been provided into the Exocrine Pancreatic Insufficiency (EPI) epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Exocrine Pancreatic Insufficiency (EPI) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of Exocrine Pancreatic Insufficiency (EPI) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Exocrine Pancreatic Insufficiency (EPI) market.

Report Highlights
• In the coming years, Exocrine Pancreatic Insufficiency (EPI) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Exocrine Pancreatic Insufficiency (EPI) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Exocrine Pancreatic Insufficiency (EPI). Launch of emerging therapies will significantly impact the Exocrine Pancreatic Insufficiency (EPI) market.
• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Exocrine Pancreatic Insufficiency (EPI) Report Insights
• Patient Population
• Therapeutic Approaches
• Exocrine Pancreatic Insufficiency (EPI) Pipeline Analysis
• Exocrine Pancreatic Insufficiency (EPI) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Exocrine Pancreatic Insufficiency (EPI) Report Key Strengths
• 11 Year Forecast
• 7MM Coverage
• Exocrine Pancreatic Insufficiency (EPI) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market

• Drugs Uptake

Exocrine Pancreatic Insufficiency (EPI) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:
• What was the Exocrine Pancreatic Insufficiency (EPI) market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Exocrine Pancreatic Insufficiency (EPI) total market size as well as market size by therapies across the 7MM during the forecast period (2020–2030)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Exocrine Pancreatic Insufficiency (EPI) market size during the forecast period (2020–2030)?
• At what CAGR, the Exocrine Pancreatic Insufficiency (EPI) market is expected to grow at the 7MM level during the forecast period (2020–2030)?
• What would be the Exocrine Pancreatic Insufficiency (EPI) market outlook across the 7MM during the forecast period (2020–2030)?
• What would be the Exocrine Pancreatic Insufficiency (EPI) market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:
• What is the disease risk, burden and unmet needs of Exocrine Pancreatic Insufficiency (EPI)?
• What is the historical Exocrine Pancreatic Insufficiency (EPI) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Exocrine Pancreatic Insufficiency (EPI) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Exocrine Pancreatic Insufficiency (EPI)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Exocrine Pancreatic Insufficiency (EPI) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
• What are the current options for the treatment of Exocrine Pancreatic Insufficiency (EPI) along with the approved therapy?
• What are the current treatment guidelines for the treatment of Exocrine Pancreatic Insufficiency (EPI) in the US and Europe?
• What are the Exocrine Pancreatic Insufficiency (EPI) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Exocrine Pancreatic Insufficiency (EPI)?
• How many therapies are developed by each company for the treatment of Exocrine Pancreatic Insufficiency (EPI)?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of Exocrine Pancreatic Insufficiency (EPI)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Exocrine Pancreatic Insufficiency (EPI) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Exocrine Pancreatic Insufficiency (EPI) and their status?
• What are the key designations that have been granted for the emerging therapies for Exocrine Pancreatic Insufficiency (EPI)?
• What are the 7MM historical and forecasted market of Exocrine Pancreatic Insufficiency (EPI)?

Reasons to buy
The report will help in developing business strategies by understanding trends shaping and driving the Exocrine Pancreatic Insufficiency (EPI).
To understand the future market competition in the asprgillosis market and Insightful review of the key market drivers and barriers.
Organize sales and marketing efforts by identifying the best opportunities for Exocrine Pancreatic Insufficiency (EPI) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
Organize sales and marketing efforts by identifying the best opportunities for Exocrine Pancreatic Insufficiency (EPI) market.
To understand the future market competition in the Exocrine Pancreatic Insufficiency (EPI) market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Irritable Bowel Syndrome Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type [IBS with Diarrhea, IBS with Constipation, and Mixed IBS ], Product, and Distribution Channel

  • $ 4550
  • May 2021
  • 180 pages

The irritable bowel syndrome (IBS) treatment market was valued at US$ 2,153.89 million in 2020 and is projected to reach US$ 4,600.30 million by 2028; it is expected to grow at a CAGR of 9.95% during ...

  • World
  • APAC
  • Gastrointestinal Drug
  • Digestive System Disorder
  • Industry analysis
  • Diagnostic Revenue
  • Drug Approval

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on